increased accumulation of putrescine, spermidine and spermine, and that a-Difluoromethyl ornithine (DFMO), an irreversible inhibitor of ornithine decarboxylase (ODC), can specifically inhibit caerulein induced pancreatic hypertrophy. These data lend further support to the involvement of ODC and polyamines in induced pancreatic growth, but up to now the study of the mechanisms involved is restricted by the lack of a suitable in vitro model.
tors, does not compete for gastrin binding. This indicates the existence of a subclass of gastrin binding sites. Difluoromethyl ornithine (DFMO) (1 mM), an irreversible inhibitor of ODC, inhibits cell growth from day 3 up to day 7 . This growth inhibition is dose dependent and closely related to an intracellular polyamine modulation. Putrescine and spermidine levels fell under detectable values while spermine levels increased. All these data suggest that this cell line could be a useful in vitro model to study the mechanisms of gastrin induced growth control.
Growth of the pancreatic tissue can be stimulated by gastrointestinal hormones such as cholecystokinin, gastrin, secretin, and analogues.2 Morisset and coworkers' have recently demonstrated that caerulein induced pancreatic growth is associated with an increased accumulation of putrescine, spermidine and spermine, and that a-Difluoromethyl ornithine (DFMO) , an irreversible inhibitor of ornithine decarboxylase (ODC), can specifically inhibit caerulein induced pancreatic hypertrophy. These data lend further support to the involvement of ODC and polyamines in induced pancreatic growth, but up to now the study of the mechanisms involved is restricted by the lack of a suitable in vitro model.
In the present study using the AR42J cell line in which CCK receptors and stimulation of amylase release by CCK peptides have already been demonstrated,5 we investigated the presence of gastrin binding sites and the possible modulation of cell proliferation by an inhibitor of ODC activity. resulted in rapid dissociation of bound radioactivity with a half time of about 8-5 min. Analysis of the displacement curves of the labelled G-17ns by CCK and gastrin peptides showed that CCK8 and G17ns inhibited the binding with the same potency (Fig. 2) and G/CCK4 also inhibited 125I-BH(2-17)-G17ns binding with C50 of 10-9 M, 16 10-9 and 10-7 M respectively. Dibutyryl cyclic GMP, a non-peptidic antagonist specific for CCK receptors, did not affect the radioligand binding (Fig. 2) . 125I-(Thr,Nle)-CCK binding results were in good agreement with those obtained by Logsdon5 using 125I-CCK39 a radioligand. Furthermore we showed that gastrin peptide inhibited 1251-(Thr,Nle)-CCK binding with a high affinity and that dibutyryl cyclic GMP partially blocked (60 %) CCK binding at the highest dose tested (10-3 M).
Methods
The ratio gastrin preferring receptors v CCKpreferring receptors was found to be 0 107 + 0.011.
Discussion
The present study investigates the interaction of 1251.1 BH-(2-17)-Gl7ns with a rat pancreatic acinar cell line (AR42J) and demonstrates the ability of DFMO to modulate cell growth and intracellular polyamine content.
125I-BH-(2-17)-Gl7ns binding data indicated that gastrin receptor sites are present in AR42J cells. The ability of the different molecules tested to inhibit gastrin binding is similar to that found in dog pancreatic acini.7 In AR42J cells radioiodinated gastrin binds with a high affinity to specific sites, in contrast to that observed in rat acini.9 CCK8 is about as potent as G17ns, whereas CCK8ns, Gs and CCK4 
